Bristol-Myers Squibb Company (BMS) have announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion in the European Union approving the ClickJect Pre-Filled Pen, a new autoinjector delivery device for Orencia (abatacept) for use in adult patients with moderate to severe active rheumatoid arthritis (RA) in combination with methotrexate after inadequate DMARD response.
Abatacept now offers a portfolio of three administration options, in the form of two subcutaneous (SC) self-injections; a pre-filled pen and the pre-filled syringe, as well as by intravenous infusion (IV).
“The new pre-filled pen offers patients with moderate to severe active RA a further administration option,” said Dr Andrew Östör, Director of the Rheumatology Clinical Research Unit, Addenbrooke’s Hospital, Cambridge. “This new delivery option provides patients the choice and flexibility they need in order to remain focused on their daily lives.”
RA is a chronic autoimmune disease that causes inflammation in the joints. The main symptoms are joint pain and swelling. It can develop at any age, but most commonly starts between the ages of 40 and 60. It is two to three times more common in women than in men. In the UK, 690,000 are affected by RA, a painful condition which can cause severe disability and ultimately affect a person’s ability to carry out everyday tasks. More than 50% of people with RA have to stop working and give up their jobs within six years of being diagnosed because of their disease. Early treatment can reduce joint damage and limit the impact of RA on a person’s quality of life. There are different medicines for the treatment of RA, some of which aim to relieve symptoms and others which help to slow the progression of the condition.